FDA Brief

Warning letters Drugs

FDA warning letter to

Green Pharmaceutical Co. Ltd.

High riskIssued Aug 23, 2023Posted Sep 5, 2023Center for Drug Evaluation and Research | CDER

FDA warns South Korea's Green Pharmaceutical over OTC drug CGMP failures, including missing identity testing and weak quality unit.

What happened

FDA reviewed records Green Pharmaceutical submitted after FDA's March 3, 2023 request under section 704(a)(4); there was no inspection. FDA found the company did not test each incoming component lot for identity, including high-risk components, and its quality unit did not properly approve or reject components. FDA cited CGMP violations and placed the firm on Import Alert 66-40 on July 17, 2023.

What FDA found

  1. The firm did not perform at least one identity test on each incoming component lot, including high-risk components, to confirm identity and safety limits.

    21 CFR 211.84(d)(1)
  2. The firm's quality unit did not adequately exercise its authority to approve or reject components and oversee quality.

    21 CFR 211.22(a)

What FDA wants

FDA asks the company to respond in writing within 30 working days and to provide certain high-risk component test results within 30 calendar days, along with a risk assessment and corrective actions. FDA also recommends a qualified CGMP consultant if the firm intends to resume making drugs for the U.S. market.

Who should pay attention

  • US brands and importers of OTC drugs made by this firm
  • distributors sourcing South Korean OTC drug products
  • drugmakers using high-risk raw materials that require identity testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk